Mesoblast Limited vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.38. The key difference: Mesoblast Limited is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| MESO | YMAG | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $20.96 | $15.98 |
52-Week Low | $12.88 | $10.76 |
Enterprise Value | $2.21B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
YMAG trades at $11.58, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.07 to $0.40 per share. News highlights ongoing distribution announcements and analysis of its option income strategy, though key financial ratios are not provided in the data.
The outlook hinges on YMAG's ability to sustain high distributions through its option strategy, but earnings volatility in underlying holdings poses a risk to NAV stability. Investor sentiment is mixed, with some analysts viewing it as a tactical buy in rangebound markets, while others caution on compounded decay across its seven underlying ETFs.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →